<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05020236</url>
  </required_header>
  <id_info>
    <org_study_id>C1071005</org_study_id>
    <secondary_id>2021-000044-22</secondary_id>
    <secondary_id>MAGNETISMM-5</secondary_id>
    <nct_id>NCT05020236</nct_id>
  </id_info>
  <brief_title>MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma</brief_title>
  <acronym>MAGNETISMM-5</acronym>
  <official_title>AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether the BCMA-CD3 bispecific antibody&#xD;
      elranatamab, alone and/or in combination with the anti-CD38 monoclonal antibody, daratumumab,&#xD;
      can provide more benefit to people with multiple myeloma compared to a combination therapy&#xD;
      including daratumumab, pomalidomide, and dexamethasone. People with multiple myeloma who have&#xD;
      received previous treatment including lenalidomide and a proteasome inhibitor will be&#xD;
      enrolled in the study. Part 1 of the study will assess the safety and activity of different&#xD;
      doses of elranatamab in combination with daratumumab. People participating in Part 2 of the&#xD;
      study will be randomly assigned to receive either elranatamab alone, elranatamab plus&#xD;
      daratumumab, or daratumumab, pomalidomide, and dexamethasone. Part 2 will compare the safety&#xD;
      and activity of (1) elranatamab alone compared to daratumumab, pomalidomide, and&#xD;
      dexamethasone, and (2) elranatamab plus daratumumab compared to daratumumab, pomalidomide,&#xD;
      and dexamethasone. Participants in both parts of the study will receive study treatment until&#xD;
      their disease progresses, they experience unacceptable side effects, or they choose to no&#xD;
      longer participate in the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 4, 2021</start_date>
  <completion_date type="Anticipated">February 20, 2026</completion_date>
  <primary_completion_date type="Anticipated">October 21, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1 Safety Lead-In: Incidence of dose limiting toxicities</measure>
    <time_frame>First 42 days after first elranatamab dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 Randomized: Progression free survival per International Myeloma Working Group criteria</measure>
    <time_frame>From date of randomization to date of progressive disease, discontinuation from the study, death, or censoring, whichever occurs first, assessed up to 32 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1 Safety Lead-In: Progression free survival per International Myeloma Working Group criteria</measure>
    <time_frame>From date of randomization to date of progressive disease, discontinuation from study, death, or censoring, whichever occurs first, assessed up to 32 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From date of randomization to date of discontinuation from study, death, or censoring, whichever occurs first, assessed up to 32 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate per International Myeloma Working Group criteria</measure>
    <time_frame>From date of randomization to date of progressive disease, discontinuation from study, death, or start of new anticancer therapy, whichever occurs first, assessed up to 32 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response per International Myeloma Working Group criteria</measure>
    <time_frame>From date of confirmed objective response to date of progressive disease, discontinuation from study, death, or censoring, whichever occurs first, assessed up to 32 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response per International Myeloma Working Group criteria</measure>
    <time_frame>From date of randomization to date of confirmed objective response, assessed up to 32 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response rate per International Myeloma Working Group criteria</measure>
    <time_frame>From date of randomization to date of progressive disease, discontinuation from study, death, or start of new anticancer therapy, whichever occurs first, assessed up to 32 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of complete response per International Myeloma Working Group criteria</measure>
    <time_frame>From date of confirmed complete response to date of progressive disease, discontinuation from study, death, or censoring, whichever occurs first, assessed up to 32 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal residual disease negativity rate per International Myeloma Working Group criteria</measure>
    <time_frame>From date of randomization to date of progressive disease, discontinuation from study, death, or start of new anticancer therapy, whichever occurs first, assessed up to 32 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained minimal residual disease negativity rate per International Myeloma Working Group criteria</measure>
    <time_frame>From date of randomization to date of progressive disease, discontinuation from study, death, or start of new anticancer therapy, whichever occurs first, assessed up to 32 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival on next-line treatment per International Myeloma Working Group criteria</measure>
    <time_frame>From date of randomization to date of second objective disease progression, discontinuation from the study, death, or censoring, whichever occurs first, assessed up to 32 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of treatment-emergent adverse events</measure>
    <time_frame>From date of first dose of study intervention through minimum of 90 days after last study intervention administration. Reporting of non-serious AEs ends at start of new anti-cancer therapy.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of abnormal laboratory results</measure>
    <time_frame>From date of first dose of study intervention through minimum of 90 days after last study intervention administration. Reporting of non-serious AEs ends at start of new anti-cancer therapy.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Grade â‰¥2 cytokine release syndrome</measure>
    <time_frame>First 28 days after first elranatamab dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elranatamab pharmacokinetics by pre- and post-dose concentrations</measure>
    <time_frame>From date of first dose through up to 14 days after date of last dose of elranatamab</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elranatamab immunogenicity by anti-drug antibodies against elranatamab</measure>
    <time_frame>From date of first dose through up to 14 days after date of last dose of elranatamab</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daratumumab pharmacokinetics by pre-dose concentrations</measure>
    <time_frame>From date of first dose through up to 14 days after date of last dose of daratumumab</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30</measure>
    <time_frame>From date of informed consent through up to 35 days after date of last dose of study intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Myeloma 20</measure>
    <time_frame>From date of informed consent through up to 35 days after date of last dose of study intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">476</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Part 1 Safety Lead-In Dose Escalation: Elranatamab + Daratumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Randomized Arm A: Elranatamab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Randomized Arm B: Elranatamab + Daratumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Randomized Arm C: Daratumumab + Pomalidomide + Dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elranatamab</intervention_name>
    <description>subcutaneous</description>
    <arm_group_label>Part 1 Safety Lead-In Dose Escalation: Elranatamab + Daratumumab</arm_group_label>
    <arm_group_label>Part 2 Randomized Arm A: Elranatamab</arm_group_label>
    <arm_group_label>Part 2 Randomized Arm B: Elranatamab + Daratumumab</arm_group_label>
    <other_name>PF-06863135</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab</intervention_name>
    <description>Daratumumab / hyaluronidase, subcutaneous</description>
    <arm_group_label>Part 1 Safety Lead-In Dose Escalation: Elranatamab + Daratumumab</arm_group_label>
    <arm_group_label>Part 2 Randomized Arm B: Elranatamab + Daratumumab</arm_group_label>
    <arm_group_label>Part 2 Randomized Arm C: Daratumumab + Pomalidomide + Dexamethasone</arm_group_label>
    <other_name>Darzalex Faspro; Darzalex solution for injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide</intervention_name>
    <description>oral</description>
    <arm_group_label>Part 2 Randomized Arm C: Daratumumab + Pomalidomide + Dexamethasone</arm_group_label>
    <other_name>Pomalyst, Imnovid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>oral</description>
    <arm_group_label>Part 2 Randomized Arm C: Daratumumab + Pomalidomide + Dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Prior diagnosis of multiple myeloma as defined by IMWG criteria (Rajkumar et al,&#xD;
             2014).&#xD;
&#xD;
          -  Measurable disease based on IMWG criteria as defined by at least 1 of the following:&#xD;
&#xD;
               -  Serum M-protein â‰¥0.5 g/dL by SPEP.&#xD;
&#xD;
               -  Urinary M-protein excretion â‰¥200 mg/24 hours by UPEP.&#xD;
&#xD;
               -  Serum immunoglobulin FLC â‰¥10 mg/dL (â‰¥100 mg/L) AND abnormal serum immunoglobulin&#xD;
                  kappa to lambda FLC ratio (&lt;0.26 or &gt;1.65).&#xD;
&#xD;
          -  Prior anti-multiple myeloma therapy including treatment with lenalidomide and a&#xD;
             proteasome inhibitor.&#xD;
&#xD;
          -  ECOG performance status â‰¤1.&#xD;
&#xD;
          -  Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade â‰¤1.&#xD;
&#xD;
          -  Not pregnant and willing to use contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Smoldering multiple myeloma.&#xD;
&#xD;
          -  Plasma cell leukemia.&#xD;
&#xD;
          -  Systemic amyloid light chain amyloidosis.&#xD;
&#xD;
          -  POEMS Syndrome.&#xD;
&#xD;
          -  Stem cell transplant within 12 weeks prior to enrolment, or active graft versus host&#xD;
             disease.&#xD;
&#xD;
          -  Active HBV, HCV, SARS-CoV2, HIV, or any active, uncontrolled bacterial, fungal, or&#xD;
             viral infection.&#xD;
&#xD;
          -  Any other active malignancy within 3 years prior to enrolment, except for adequately&#xD;
             treated basal cell or squamous cell skin cancer, or carcinoma in situ.&#xD;
&#xD;
          -  Previous treatment with a BCMA-directed therapy.&#xD;
&#xD;
          -  Anti-CD38-directed therapy within 6 months preceding the first dose of treatment in&#xD;
             this study.&#xD;
&#xD;
          -  Live attenuated vaccine within 4 weeks of the first dose of study intervention.&#xD;
&#xD;
          -  Administration with an investigational product (e.g. drug or vaccine) concurrent with&#xD;
             study intervention or within 30 days or 5 half-lives preceding the first dose of study&#xD;
             intervention used in this study (whichever is longer).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hamamatsu University Hospital</name>
      <address>
        <city>Hamamatsu</city>
        <state>Shizuoka</state>
        <zip>431-3192</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [seoul]</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [seoul]</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pratia Onkologia Katowice</name>
      <address>
        <city>Katowice</city>
        <zip>40-519</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Pratia Poznan</name>
      <address>
        <city>Skorzewo</city>
        <zip>60-185</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Politecnico La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>SÃ¶dra Ã„lvsborg Sjukhus</name>
      <address>
        <city>BorÃ¥s</city>
        <zip>501 82</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitetssjukhuset Ãƒ-rebro</name>
      <address>
        <city>Ã–rebro</city>
        <state>Ã–rebro LÃ„N [se-18]</state>
        <zip>701 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C1071005</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 11, 2021</study_first_submitted>
  <study_first_submitted_qc>August 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Elranatamab</keyword>
  <keyword>PF-06863135</keyword>
  <keyword>B-Cell Maturation Antigen</keyword>
  <keyword>BCMA</keyword>
  <keyword>Bispecific antibody</keyword>
  <keyword>BCMA-CD3 bispecific antibody</keyword>
  <keyword>Daratumumab</keyword>
  <keyword>Pomalidomide</keyword>
  <keyword>Multiple myeloma</keyword>
  <keyword>Relapsed multiple myeloma</keyword>
  <keyword>Refractory multiple myeloma</keyword>
  <keyword>MagnetisMM-5</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

